Health Bulletin 02/September/2023

Here are the Top health stories for the day:

Death of pregnant doctor due to delayed medical attention: HC sets aside WBCERC order, directs re-adjudication of case

Setting aside the order of the West Bengal Clinical Establishment Regulatory Commission (WBCERC), the Calcutta High Court has directed the Commission to re-adjudicate the case concerning the death of a pregnant doctor, who passed away because of refusal of treatment and delayed medical attention by 3 hospitals.

The WBCERC held only Bhagirathi Neotia Woman & Child Care Centre (BNWCCC) responsible and asked it to pay Rs 20 lakh for negligence in the treatment of the deceased. However, while considering the plea by BNWCCC the Calcutta High Court bench expressed its surprise at the fact that no complaint was filed against Apollo Hospital, where the patient was taken at first and was denied treatment or Belle Vue hospital, which kept the patient waiting for 35 minutes before commencing treatment.

For more details, check out the link given below:

Death Of Pregnant Doctor Due To Delayed Medical Attention: HC Sets Aside WBCERC Order, Directs Re-Adjudication Of Case

100 percent MBBS seats reservation for local candidates in 'competent authority quota' in Telangana: SC refuses to interfere

The Supreme Court has denied interfering with a plea that challenged the Telangana Government's reservation of 100% MBBS/BDS seats for the local candidates under the 'competent authority quota' in the medical colleges established after June 2014.

This reservation policy was introduced by the State Government by an order dated July 3, 2023. The State has contended that the introduction of this reservation policy is an effort to provide the students belonging to Telangana with a better opportunity for enrolling in a local medical college within the State, which is in line with the State's aim to bolster local healthcare services and access to medical education.

For more details, check out the link given below:

100 Percent MBBS Seats Reservation For Local Candidates In 'Competent Authority Quota' In Telangana: SC Refuses To Interfere

Synokem gets CDSCO panel nod to manufacture, market antidiabetic FDC Pioglitazone, Vildagliptin

With the condition of conducting phase IV clinical trial, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has given its nod to the drug major Synokem Pharmaceutical for manufacturing and marketing the antidiabetic fixed-dose combination (FDC) drug Pioglitazone plus Vildagliptin film coated bilayered tablet.

This came after Synokem Pharmaceutical presented the clinical trial report of Pioglitazone plus Vildagliptin (30mg/100mg +15mg/100mg) film-coated bilayered tablet, before the committee. The committee noted that the firm has already presented a bioequivalence (BE) study report in the SEC meeting held on 09.09.2022.

For more details, check out the link given below:

Synokem Gets CDSCO Panel Nod To Manufacture, Market Antidiabetic FDC Pioglitazone, Vildagliptin